Know Cancer

forgot password

A Multicenter Non-randomized Phase II Study to Evaluate Nab-paclitaxel in Metastatic Brest Cancer Patients Failing a Solvent Based Taxane as (Neo-)Adjuvant Treatment (Tiffany)

Phase 2
18 Years
Not Enrolling
Metastatic Breast Cancer

Thank you

Trial Information

A Multicenter Non-randomized Phase II Study to Evaluate Nab-paclitaxel in Metastatic Brest Cancer Patients Failing a Solvent Based Taxane as (Neo-)Adjuvant Treatment (Tiffany)

Primary Objective:

To determine overall response rate (ORR) and to exclude that it is 20% or lower.

Secondary Objectives:

1. To determine compliance and toxicity of the therapy.

2. To determine clinical benefit rate (CBR) in patients with measurable disease.

3. To determine duration of response.

4. To determine progression-free survival (PFS).

5. To determine overall survival.

6. To assess biomarkers, e.g. SPARC expression in the tissue of the primary or metastatic

Inclusion Criteria:

- Written informed consent for all study procedures according to local regulatory
requirements prior to beginning specific protocol procedures.

- Complete baseline documentation must be submitted via the web-based data collection
system MedCODES to the GBG Forschungs GmbH.

- Diagnosis of locally advanced or metastatic hormone-sensitive or insensitive,
HER2-negative or -positive breast cancer.

- Relapse within ≤ 12 months after completing (last day of last cycle) (neo-) adjuvant

- Documented relapse of either a measurable or a non-measurable lesion according to the
modified RECIST criteria.

- Previous neoadjuvant or adjuvant treatment with a solvent based taxane (paclitaxel or
docetaxel) irrespective of dose and duration.

- Prior endocrine treatment for metastatic / advanced disease is allowed.

- Complete radiological and clinical tumor assessment within 4 weeks prior to
registration performed as clinically indicated.

- Age ≥ 18 years.

- ECOG Performance Status ≤ 2 (irrespective of restrictions due to breast cancer).

- Laboratory requirements:Absolute neutrophil count (ANC) >= 1.5 x 109/L., Platelets
>= 100 x 109/L., Hemoglobin >= 9 g/dL (>= 5.6 mmol/L)., Prothrombin time (PT) or
international normalized ratio (INR) <= 1.2x ULN (upper normal limit), Partial
thromboplastin time (PTT) <= 1.2x ULN, Total bilirubin < 1.5x ULN, ASAT (SGOT) and
ALAT (SGPT) <= 2.5x ULN (concomitant elevations in serum bilirubin and ASAT/ALAT
above 1.0x ULN are not permitted), Creatinine clearance >= 50 mL/min), Urine
Protein to Creatinine Ratio (UPC) < 1 (if UPC >= 1, then 24-hour urine protein must
be < 1 g).

- Normal cardiac function confirmed by ECG.

- A female either of: 1) Non-childbearing potential, i.e. physiologically incapable of
becoming pregnant because of history of hysterectomy, bilateral oophorectomy
(ovariectomy), bilateral tubal ligation or postmenopausal status.

2) Childbearing potential with a negative pregnancy test (urine or serum)within 2
weeks prior to registration, preferably as close to the first dose as possible, and
agrees to use adequate contraception.

Acceptable contraceptive methods, when used consistently and in accordance with both the
product label and the instructions of the physician, are as follows:

An intrauterine device with a documented failure rate of less than 1% per year,
Vasectomised partner who is sterile prior to the female subject's entry and is the sole
sexual partner for that female, Complete abstinence from sexual intercourse for 14 days
before exposure to the investigational product, through the dosing period, and for at
least 21 days after the last dose of investigational product, Double-barrier
contraception (condom with spermicidal jelly, foam suppository, or film; diaphragm with
spermicide; or male condom and diaphragm with spermicide).

- Female subjects who are lactating should discontinue nursing prior to the first dose
of study drug and should refrain from nursing throughout the treatment period and for
14 days following the last dose of study drug.

Exclusion Criteria:

- Known or suspected hypersensitivity reaction to the investigational compounds or
incorporated substances.

- (Neo-)adjuvant therapy not containing a solvent based taxane.

- (Neo-)adjuvant therapy with nab-paclitaxel.

- Concurrent hormonal therapy for cancer.

- Life expectancy less than 3 months.

- Pre-existing peripheral neuropathy of > grade 2 (per CTCAE).

- Pre-existing grade 3 or 4 diarrhea.

- Presence of uncontrolled infection.

- Any serious and/or unstable pre-existing medical, psychiatric, or other condition
that could interfere with the subject's safety, provision of informed consent, or
compliance to study procedures.

- Concurrent specific systemic anti-tumor treatment or treatment with experimental
compounds during study treatment.

Type of Study:


Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Overall response rate (ORR)

Outcome Time Frame:

3 years

Safety Issue:



Germany: Federal Institute for Drugs and Medical Devices

Study ID:

GBG 65



Start Date:

July 2011

Completion Date:

October 2012

Related Keywords:

  • Metastatic Breast Cancer
  • German Breast Group
  • GBG Forschungs GmbH
  • GBG
  • GBG 65
  • Tiffany
  • Breast Cancer
  • Metastatic Breast Cancer
  • Nab-Paclitaxel
  • Abraxane
  • Taxane Failure
  • Breast Neoplasms